Conducting a Virtual Clinical Trial in HER2-Negative Breast Cancer Using a Quantitative Systems Pharmacology Model With an Epigenetic Modulator and Immune Checkpoint Inhibitors.
computational model
epigenetic modulator
immune checkpoint inhibitor
immuno-oncology
quantitative systems pharmacology
systems biology
virtual clinical trial
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
05
12
2019
accepted:
11
02
2020
entrez:
12
3
2020
pubmed:
12
3
2020
medline:
12
3
2020
Statut:
epublish
Résumé
The survival rate of patients with breast cancer has been improved by immune checkpoint blockade therapies, and the efficacy of their combinations with epigenetic modulators has shown promising results in preclinical studies. In this prospective study, we propose an ordinary differential equation (ODE)-based quantitative systems pharmacology (QSP) model to conduct an
Identifiants
pubmed: 32158754
doi: 10.3389/fbioe.2020.00141
pmc: PMC7051945
doi:
Types de publication
Journal Article
Langues
eng
Pagination
141Subventions
Organisme : NCI NIH HHS
ID : R01 CA138264
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA212007
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186691
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA186717
Pays : United States
Informations de copyright
Copyright © 2020 Wang, Sové, Jafarnejad, Rahmeh, Jaffee, Stearns, Torres, Connolly and Popel.
Références
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 2005 Jun 10;23(17):3912-22
pubmed: 15851766
PLoS One. 2019 Mar 4;14(3):e0213186
pubmed: 30830950
Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9
pubmed: 25071169
Prog Biophys Mol Biol. 2018 Nov;139:15-22
pubmed: 29902482
J Immunol. 2005 Aug 1;175(3):1575-85
pubmed: 16034096
Asian Pac J Cancer Prev. 2018 Mar 27;19(3):777-783
pubmed: 29582634
Clin Cancer Res. 2018 Feb 1;24(3):511-520
pubmed: 28801472
Methods. 2014 Jan 1;65(1):95-104
pubmed: 23872324
Exp Mol Med. 2018 Dec 13;50(12):1-11
pubmed: 30546008
Clin Cancer Res. 2017 Sep 1;23(17):5187-5201
pubmed: 28698201
J Clin Oncol. 2014 Sep 20;32(27):2959-66
pubmed: 25071121
Sci Rep. 2019 Aug 2;9(1):11286
pubmed: 31375756
PLoS Comput Biol. 2019 Nov 27;15(11):e1007495
pubmed: 31774808
Rheumatology (Oxford). 2010 Aug;49(8):1447-60
pubmed: 20421217
AAPS J. 2019 Jun 24;21(5):79
pubmed: 31236847
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5411-7
pubmed: 17875771
Clin Cancer Res. 2019 Sep 15;25(18):5717-5726
pubmed: 31227501
Science. 2019 May 10;364(6440):558-566
pubmed: 31000591
Nat Rev Immunol. 2014 Sep;14(9):619-29
pubmed: 25145757
Mol Cancer Ther. 2008 Aug;7(8):2517-27
pubmed: 18723496
Cancer Lett. 2007 Jul 8;252(1):86-92
pubmed: 17257744
Nat Commun. 2014 Oct 28;5:5241
pubmed: 25348003
NPJ Breast Cancer. 2018 Jan 11;4:1
pubmed: 29354686
Cancer Manag Res. 2018 Dec 10;10:6823-6833
pubmed: 30573992
CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):777-791
pubmed: 31535440
Clin Cancer Res. 2017 Dec 1;23(23):7199-7208
pubmed: 28939740
AAPS J. 2019 Jun 3;21(4):72
pubmed: 31161268
Curr Opin Pharmacol. 2017 Aug;35:48-56
pubmed: 28609681
Br J Clin Pharmacol. 2014 Jul;78(1):106-17
pubmed: 24433434
BMC Med. 2019 May 9;17(1):90
pubmed: 31068190
Cancer Cell. 2018 Apr 9;33(4):649-663.e4
pubmed: 29576375
Cell Biosci. 2018 Apr 18;8:30
pubmed: 29713453
CPT Pharmacometrics Syst Pharmacol. 2017 Jan;6(1):58-66
pubmed: 28019091
Oncotarget. 2016 Feb 16;7(7):7390-402
pubmed: 26862729
AAPS J. 2017 Jul;19(4):1002-1016
pubmed: 28540623
CPT Pharmacometrics Syst Pharmacol. 2018 Mar;7(3):135-146
pubmed: 29349875
Sci Rep. 2018 Feb 28;8(1):3753
pubmed: 29491381
Cancer Immunol Res. 2018 Dec;6(12):1561-1577
pubmed: 30341213
Cancer Discov. 2018 Sep;8(9):1069-1086
pubmed: 30115704
Future Oncol. 2017 Jun;13(13):1137-1148
pubmed: 28326839
Ann Oncol. 2019 Mar 1;30(3):397-404
pubmed: 30475950
Front Oncol. 2019 Jan 23;9:10
pubmed: 30729096
R Soc Open Sci. 2019 May 22;6(5):190366
pubmed: 31218069
Proc Natl Acad Sci U S A. 2018 Apr 10;115(15):3912-3917
pubmed: 29581255
Clin Cancer Res. 2019 Jun 1;25(11):3469-3470
pubmed: 31160495
J Med Chem. 2003 Feb 27;46(5):820-30
pubmed: 12593661
J Theor Biol. 2019 May 21;469:47-60
pubmed: 30836073
J Theor Biol. 2008 Sep 7;254(1):178-96
pubmed: 18572196
Front Pharmacol. 2018 Jan 31;9:41
pubmed: 29445339
Cancer Immunol Res. 2018 Oct;6(10):1260-1273
pubmed: 30012633
J Dermatol Sci. 2014 Aug;75(2):140-7
pubmed: 24866536
CPT Pharmacometrics Syst Pharmacol. 2016 Mar;5(3):140-6
pubmed: 27069777
Oncoimmunology. 2016 Aug 31;5(11):e1219008
pubmed: 27999738
Rep Biochem Mol Biol. 2018 Oct;7(1):30-37
pubmed: 30324115
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Molecules. 2013 Nov 14;18(11):14085-95
pubmed: 24241152
J Transl Med. 2018 Apr 3;16(1):86
pubmed: 29615076
Br J Surg. 2016 Jun;103(7):845-54
pubmed: 26953091
Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5
pubmed: 25918390
Clin Cancer Res. 2008 Jul 15;14(14):4517-25
pubmed: 18579665
Breast Cancer Res Treat. 2013 Jul;140(1):13-21
pubmed: 23828498
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
Oncoimmunology. 2018 Jul 30;7(10):e1490854
pubmed: 30386679
J Immunother Cancer. 2018 Jan 30;6(1):10
pubmed: 29382395
Breast Cancer Res Treat. 2018 Aug;170(3):477-486
pubmed: 29594759
J Clin Oncol. 2013 Jun 10;31(17):2128-35
pubmed: 23650416
Cancer Res. 2008 Jul 1;68(13):5439-49
pubmed: 18593947
Immunity. 2016 Jun 21;44(6):1255-69
pubmed: 27332730
Science. 2014 Nov 28;346(6213):1123-7
pubmed: 25430770
J Clin Oncol. 2021 Aug 1;39(22):2443-2451
pubmed: 33844595
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336685
PLoS Comput Biol. 2019 Nov 18;15(11):e1007468
pubmed: 31738746
Ann Oncol. 2019 Mar 1;30(3):405-411
pubmed: 30475947
Cancer J. 2017 Jan/Feb;23(1):10-22
pubmed: 28114250
Mol Oncol. 2017 Jul;11(7):824-846
pubmed: 28614624
Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4592-7
pubmed: 10200307
Cancer Res. 2001 Feb 1;61(3):931-4
pubmed: 11221885
Nat Genet. 2016 Jul;48(7):725-32
pubmed: 27240091
Blood. 2007 Apr 1;109(7):2781-90
pubmed: 17179232
Oncol Lett. 2017 Aug;14(2):1766-1774
pubmed: 28789407